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Abstract
Sera from 25 metastatic breast cancer patients and 25 healthy controls were subjected to affinity chromatography using
immobilized galectin-1. Serum from the healthy subjects contained on average 1.2 mg per ml (range 0.7–2.2) galectin-1
binding glycoproteins, whereas serum from the breast cancer patients contained on average 2.2 mg/ml (range 0.8–3.9),
with a higher average for large primary tumours. The major bound glycoproteins were a-2-macroglobulin, IgM and
haptoglobin. Both the IgM and haptoglobin concentrations were similar in cancer compared to control sera, but the
percentage bound to galectin-1 was lower for IgM and higher for haptoglobin: about 50% (range 20–80) in cancer sera and
about 30% (range 25–50) in healthy sera. Galectin-1 binding and non-binding fractions were separated by affinity
chromatography from pooled haptoglobin from healthy sera. The N-glycans of each fraction were analyzed by mass
spectrometry, and the structural differences and galectin-1 mutants were used to identify possible galectin-1 binding sites.
Galectin-1 binding and non-binding fractions were also analyzed regarding their haptoglobin function. Both were similar in
forming complex with haemoglobin and mediate its uptake into alternatively activated macrophages. However, after
uptake there was a dramatic difference in intracellular targeting, with the galectin-1 non-binding fraction going to a LAMP-2
positive compartment (lysosomes), while the galectin-1 binding fraction went to larger galectin-1 positive granules. In
conclusion, galectin-1 detects a new type of functional biomarker for cancer: a specific type of glycoform of haptoglobin,
and possibly other serum glycoproteins, with a different function after uptake into tissue cells.
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Introduction
A glycoprotein occurs in multiple glycoforms depending on
which glycans are attached at each particular site. Haptoglobin,
for example (Fig. 1) [1], consist of two chain subunits (ab) with four
N-glycosylation sites (Fig. 1A) [2,3], which in turn can form
dimers, trimers or higher oligomers giving each complete molecule
eight, twelve or more N-glycosylation sites (Fig. 1C). Each of these
sites can carry one out of a big collection of different N-glycans
(Fig. 1B shows four examples of the over 100 known in human
serum), making the total number of different possible glycoforms
very large. The composition and proportion of all these different
glycoforms are not random, however, but are strikingly constant
over time in each healthy individual [4], and also vary little
between most individuals in a population [5], suggesting tight
physiological regulation and function.
The glycan structures, and thereby the profile of glycoforms of
different glycoproteins, have been known for a long time to be
altered in cancer [6,7]. This has stimulated an increasing effort to
use particular glycoforms as biomarkers for cancer in serum, as
detected by combinations of plant lectins, antibodies and structural
analysis by mass spectrometry, summarized as glycoproteomics
[8,9]. These may be derived from the cancer itself [8,10,11,12],
and in fact some of the most commonly used cancer biomarkers
are carbohydrate based and detection of specific glycoforms of
other commonly used cancer associated proteins, such as PSA,
have been proposed to sharpen the diagnosis. Specific cancer
induced forms of common serum glycoproteins, such as transferrin
or haptoglobin that are synthesized mainly in the liver, have also
been observed and may serve as markers of the physiological
effects of the cancer [2,3,13,14,15].
The functional effects of the cancer-related carbohydrate
changes, however, have been more elusive. One hypothesis has
been that cancer associated carbohydrate structures modulate cell
adhesion, e.g. sialyl-Lewis X-containing glycans bind to endothe-
lial carbohydrate binding proteins, selectins, to promote metastasis
[8,16]. Another recent hypothesis is that cancer associated
carbohydrate structures modulate intracellular traffic of a
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binding proteins, the galectins. For example, tri- and tetraantenn-
ary N-glycans bind galectin-3 to increase cell surface residence
time of epidermal growth factor receptors in cancer cells, in turn
increasing cell sensitivity and growth response to EGF [6,17], and
by analogous mechanisms, galectin-1 regulates cell surface
expression of integrins [18], in turn affecting tumour cell adhesion
and migration, and cell surface expression of the calcium channel
TRPV5, in turn affecting Ca-homeostasis [19].
Galectins are a family of small animal proteins binding specific
carbohydrate chains containing b-galactosides, such as N-
acetyllactosamine (LacNAc) (Fig. 1B and C) [20,21]. Largely
independent of the research on cancer carbohydrates described
above, a number of possible relationships between galectins and
cancer, inflammation and immunity have been suggested, with
proposed effects on cell adhesion, angiogenesis, apoptosis and
various types of signaling [22,23,24]. Currently, the role in
intracellular trafficking of glycoproteins, described above, provides
Figure 1. Haptoglobin and galectin-1. A) A model of one glycoform of haptoglobin (Hp2) with the a-subunit in grey and b-subunit in white, and
N-glycans attached at the four known sites (numbers) [2,3] shown as stick models in green but with the LacNAc parts potentially binding galectin-1 in
black. A surface thought to interact with haemoglobin is shown in red and the CD163-binding site is shown in blue [65]. B) Schematics of the N-
glycans shown in panel A, with component saccharide moieties indicated. The major N-glycan of human serum is no. 4, a biantennary N-glycan
capped with NeuAca6 (6 bound sialic acid, shown as purple diamonds), which would block galectin binding [20]. The other glycans may lack one or
more of the NeuAca6, and/or have an additional antenna with a NeuAca3, all of which would open potential galectin-binding sites (see Table S3 in
Cederfur et al. [25]). C) Models of dimeric haptoglobin Hp1 and trimeric haptoglobin Hp2, built from the model of panel A, together with two human
galectin-1 dimers (pdb-id: 1W6P), colored with the two subunits in different shades of yellow, and the LacNAc-binding site (C–D, [20]) in black. The
monosaccharide symbols are as recommended by Consortium for Functional Glycomics (http://glycomics.scripps.edu/CFGnomenclature.pdf): purple
diamond, N-acetylneuraminic acid; blue square, N-acetylglucosamine; green ball, mannose; yellow ball, galactose. The coordinates for the model of
the haptoglobin peptide chains (panel A) were obtained from the SWISS-MODEL REPOSITORY(http://swissmodel.expasy.org/repository/), Model_id:
76a3bb6963a6b1ee5c09942c719f20c2_UP000020_3, which in turn is built based on the X-ray crystal structure of complement protein C1r (pdb-id:
1GPZ). Four N-glycans with structures as shown in Fig. 1C were attached to the four known N-glycosylation sites of haptoglobin and built into this
model and energy minimized using the server GlycamWeb (http://glycam.ccrc.uga.edu/ at Complex Carbohydrate Research Center, The University of
Georgia, Athens, GA). The models were visualized using The PyMOL Molecular Graphics System, Version 1.3, Schro ¨dinger, LLC. For the haptoglobin
dimer and trimer of panel C, two or three copies of the model of panel A were manually arranged to resemble the models published by Polticelli et al.
[1] regarding distances between the b-subunits.
doi:10.1371/journal.pone.0026560.g001
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cancer and also other pathophysiological conditions [6,17].
Here we propose that this link between galectins and particular
glycans may also apply to serum glycoproteins, and provide the
basis for a new type of functional biomarkers. Almost all potential
galectin binding sites on serum glycoproteins have a LacNAc
residue as a central part (Fig. 1B). However, LacNAc by itself
binds galectin with relatively low affinity (Kd,100 mM). More-
over, most of the LacNAc residues on serum glycoproteins are
capped by 2–6 sialic acid that prevents binding of all galectins as in
the major serum N-glycan (upper left structure in Fig. 1B). The
remainders of the LacNAc residues bind different galectins to a
different extent depending on the details of their structural
context, i.e. neighboring saccharides and protein parts that can
enhance or decrease binding affinity, and each galectin can be
used as a reagent to detect different glycoforms. Galectin-3 binds
relatively large fractions of a wide range of serum glycoproteins,
whereas galectin-1 binds a smaller fraction of a more restricted set
and galectin-2 binds none at all [25].
Now we show that in sera from patients with metastatic breast
cancer, galectin-1 binds on average almost twice as much
glycoprotein compared with healthy individuals, including a
fraction of haptoglobin containing N-linked glycans with less
terminal sialic acids, and increased proportion of additional
antenna (as in the bottom right structure of Fig. 1B). Moreover, the
galectin-1 bound glycoforms of haptoglobin had different
trafficking, compared to the non-bound haptoglobin, after uptake
into macrophages (in complex with haemoglobin). Thus galectin-1
detects a specific subset of this serum protein, which occurs at an
increased level in sera from cancer patients and has a different
function in tissue cells.
Materials and Methods
Patient samples
Deidentified human serum samples were used, under ethical
permit to authors HO and MF and approval from the Ethical
Review Board at Lund University (Now Regional Ethical Review
Board Lund, http://www.epn.se/lund/om-naemnden.aspx).
Written informed consent was obtained from all participants. All
information and data was handled confidentially, and evaluation
of information linked to patients was carried out in accordance
with the Swedish Personal Data Act (Personuppgiftslagen in
Swedish). Serum samples from 25 female metastatic breast cancer
patients and 25 age matched healthy female volunteers were
collected and stored as described previously [25,26]. Subject age
and pathology diagnosis are shown in Table S1.
Production of recombinant galectin
The cDNA encoding the C3S mutant of human galectin-1 was
generously provided by Dr. Jun Hirabayashi [27]. Different
mutants were made from this cDNA and confirmed by sequencing
by the same procedures as reported previously [28]. The
recombinant proteins were produced in E. coli BL21 Star and
purified by chromatography on lactosyl-Sepharose as previously
described [25].
Galectin affinity chromatography
Galectins were coupled to 1 ml NHS-activated Hi-Trap affinity
columns (Amersham Biosciences) as described by Cederfur et al.
[25]. While kept on ice, 0.1 ml serum in 1.9 ml PBS or 2 mg of
haptoglobin (pooled from human plasma, Sigma-Aldrich) in 2 ml
PBS was circulated for 30 minutes at 1 ml/min on the 1 ml
galectin-1 C3S column. The column was sealed for 30 minutes to
enhance the ligand-galectin binding. The unbound fraction (flow-
through) was saved and the column was washed with 32 column
volumes of PBS. Galectin binding proteins were eluted with
150 mM lactose in PBS, in fractions of 0.2 ml, up to five column
volumes. Protein concentrations were determined with the Bio-
Rad protein assay and fractions were kept and stored at 220uC
until further analysis. Six sera from both cancer patients and
healthy controls were analyzed a second time to evaluate the
method constancy, resulting in a within sample variation of ,8%.
A duplicate of a standard serum sample was rechromatographed
about each 10th run, to ensure that column performance
remained within this range; thus each column was used for
approximately 15 chromatographed sera. Some columns were
opened after the last use, and an aliquot from the top of the
column gel was removed, boiled in sample buffer and analyzed by
SDS-PAGE (as described for galectin-3 columns in [25]), to show
that no protein was retained after lactose elution. There was also
no evidence that the column binding capacity was exceeded, since
when selected flow through fractions were rechromatographed, no
additional glycoproteins bound. Moreover, the column could
isolate 0.6 mg haptoglobin without sign of overload as described
under results, whereas the amount bound from serum samples was
between 0.07 and 0.4 mg.
Fluorescence anisotropy assay
Fluorescence anisotropy assay was used to compare the direct
binding of different fluorescein tagged saccharide probes to
galectin-1 and mutants, and to compare the potency of small
saccharides and glycoproteins to inhibit the interaction of galectin-
1 and mutants with a high affinity thiodigalactoside-amid (tdga)-
probe, as described in detail [28].
SDS-PAGE, western blotting and proteomics
Serum ligands were analyzed by one-dimensional 4–20% SDS-
PAGE, western blotting, and MALDI-TOF of tryptic digests of
excised bands as described previously [25].
Lycopersicon Esculentum affinity chromatography
0.1 ml of human serum were added to a 1 ml column of agarose
bound Lycopersicon Esculentum (Vectorlabs) followed by exten-
sive wash (30 column volumes) with PBS. 0.3 ml flow through
fractions were collected and presence of protein was determined
using Bio-Rad protein assay. Protein containing samples were
pooled and run on a galectin-1 C3S column as described earlier.
0.1 ml of column material was removed and boiled for 5 minutes
before analyzed with SDS-PAGE as described above.
Neuraminidase treatment of serum and transferrin
0.1 ml serum or 2 mg of human transferrin (Sigma- Aldrich)
was treated with neuraminidase from Vibrio cholerae (Roche)
(25 mmol per mmol of transferrin) for 1 h at 37uC. Treated and
untreated samples were then separated by affinity chromatography
as described above.
Haptoglobin ELISA
Haptoglobin was quantitated in microtiter well immobilized
samples using biotinylated goat a-haptoglobin (Sigma Aldrich, EZ-
LinkH Sulfo-NHS-SS Biotinylation Kit, Pierce) followed by
Streptavidin horseradish peroxidase (HRP) conjugate for detec-
tion. Three independent repeat ELISA experiments, each in
duplicate, were performed in 96 well PolySorb microtitre plates
(Nunc). All wells except two (blank), were incubated with 100 mlo f
either unseparated serum samples (1:90), pooled galectin-1 bound
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human plasma, Sigma-Aldrich) (Starting at 0.2 with 1:2 dilutions)
at 4uC for 24 hours. After coating, wells were blocked with 100 ml
1% BSA for 1 hour at 37uC and then 100 ml of biotin conjugated
goat a-human haptoglobin (1:1000) were added to each well. After
1 hour incubation at RT, wells were washed 4 times with 0.05%
tween in PBS and incubated for 1 hour with 50 ml of Streptavidin
horseradish peroxidase (HRP) conjugate (1:5000) at RT. The wells
were washed 4 times with 0.05% tween in PBS and presence of
HRP was detected with TMB Peroxidase EIA substrate kit
(BioRad). Absorbance at 650 nm was measured by using
Labsystems multiscan RC plate reader (Labsystems). Blank value
was subtracted from each sample and haptoglobin content of each
serum was calculated from standard curve using nonlinear
regression in Prism 5.03 (GraphPad Software).
IgM-ELISA
IgM was quantitated in immobilized samples (two independent
repeat experiments with duplicate samples in each) by the same
procedure as described for haptoglobin above, except that
detection was with peroxidase conjugated a-human IgM
(1:1000) (Sigma-Aldrich), and a dilution series of serum with
known IgM concentration was used to construct the standard
curve.
Galectin-1competitive ELISA
Galectin-1 was quantitated in serum from 3 cancer patients
(# 1, 2 and 4) and 2 healthy controls (# 1 and 2) in 96 well plates
coated with 2 ng/ml a-rat-galectin-1 (BAbCO) antibody. Biotin
labeled recombinant galectin-1 was used as a competitor in a
concentration of 50 ng/ml. For galectin-1 biotinylation, EZ-link
sulfo-NHS-SS- Biotinylation kit (Pierce) was used as instructed. 1–
500 ng/ml of recombinant galectin-1 was used to make an inverse
standard curve. Bound biotin-galectin-1 was recognized by
1:10000 diluted avidin-HRP (BioRad). Presence of HRP was
detected with TMB Peroxidase EIA substrate kit (BioRad)
Absorbance at 650 nm was measured by using Labsystems
multiscan RC plate reader (Labsystems).
Statistical analysis and ROC-plots
All pair wise comparisons between the cancer and control sera
were done by a two tailed unpaired t-test, and receiver operating
characteristic (ROC) curves were constructed using the Prism
software.
Glycan analysis
The bound and unbound haptoglobin fractions (approximately
30 mg per line) were separated by SDS-PAGE under reducing
conditions on Novex 4–12% Bis-Tris gradient gels (Invitrogen).
Total protein was visualized by the colloidal blue staining kit
according to the instructions of the manufacturer (Invitrogen). The
excised b-haptoglobin bands were incubated overnight at 37uC
with 8 ml of PNGase F (0.5 mU) in 30 ml of 25 mM ammonium
bicarbonate to allow N-glycan release. N-glycans were separated
using an Ultimate 3000 nano-LC system (Dionex/LC Packings)
equipped with a graphitized carbon trap column (Hypercarb,
5 mm, 170 mm610 mm; Thermo Scientific) and a nano column
(75 mm6100 mm) packed by Grom Analytik. The column was
equilibrated at room temperature with eluent A (0.1% formic acid
in water) at a flow rate of 400 nL min
21. After injection of the
sample a linear gradient was applied (15 min 25% eluent B (95%
acetonitrile), 25 min 70% B, 30 min 70% B). The eluate was
monitored by absorption at 215 nm. The LC column was coupled
to an Esquire HCT-Ultra ESI-ion trap-MS (Bruker-Daltonics,
Bremen, Germany) equipped with an online nanospray source
operated in the positive-ion mode. For electrospray (1100–
1250 V), electropolished, stainless steel LC2MS emitters
(150 mm OD, 30 mm ID) from Proxeon A/S were used. The
solvent was evaporated at 170uC employing a nitrogen stream of
6 L min
21. Ions from m/z 500 to m/z 1800 were monitored in the
MS mode. When operated in the auto MS/MS mode, monitoring
ions from m/z 140 to 2200, each MS scan was followed by the
acquisition of MS/MS spectra of up to five of the most abundant
ions in the MS spectrum. Glycan structures were assigned using
GlycoWorkbench [29].
Glycopeptide analysis
Alternatively to the glycan analysis procedure, SDS-PAGE
gel pieces containing b-haptoglobin were reduced, alkylated and
digested with trypsin (Promega), as previously described [30].
After digestion, (glyco-) peptides were collected using two
rounds of extraction with 20 ml of 0.1% TFA and stored at
220uC prior to analysis by mass spectrometry. Total tryptic
digests of bound and unbound b-haptoglobin were applied to a
reverse-phase column (PepMap, 3 mm, 75 mm?100 mm; Dio-
nex/LC Packings) using an Ultimate 3000 nano-LC system
(Dionex/LC Packings). The column was equilibrated at room
temperature with eluent A (0.1% formic acid in water) at a flow
rate of 300 nL min
21. After injection of the sample a linear
gradient was applied (15 min 25% eluent B (95% acetonitrile),
25 min 70% B, 30 min 70% B). The eluate was monitored by
absorption at 215 nm. Eluates were analyzed by ESI-ion trap-
MS as described above.
Haptoglobin-haemoglobin complex
Haptoglobin (galectin-1 binding or non-binding) and haemo-
globin were added in a 1:1 weight ratio (0. 28 mg of each or
0.23 mmoles of haptoglobin and 0.40 mmoles of haemoglobin) and
left shaking for 10 minutes at room temperature in order to allow
formation of complexes. Formation of haptoglobin-haemoglobin
complexes were analyzed using a native gel electrophoresis
(without b-mercaptoethanol and SDS). Samples of approximately
10 mg of protein were added to a 4–20% polyacrylamide gel
(Pierce).
Labeling of proteins
A 15 fold access of labeling dye; NHS-Fluorescein or NHS-
Sulphorhodamine (Thermo Scientific) dissolved in DMF was
added to a 2 mg/ml protein solution in a 100 mM carbonate/
bicarbonate buffer. The solution was mixed well and incubated for
1 h at room temperature. Labeled protein was separated from the
unreacted dye by a buffer change to PBS on a PD10 column
(Amersham Biosciences).
Cell lines and cell cultures
THP-1 (Human acute monocytic leukemia cell line) (ATCC)
cells were kept in incubators at 37uC and 5% CO2. The cells were
grown in 24-well plates with RPMI-1640, supplemented with 10%
Foetal Calf Serum and 1% Penicillin-Streptomycin (Invitrogen). In
order to stimulate monocytes to differentiate into macrophages,
THP-1 cells were grown in media additionally containing 100 ng/
ml phorbol-12-myristate-13-acetate (PMA) (Sigma-Aldrich) for
five days and 10 ng/ml Il-4 for 2 days. Untreated cells were
transferred to a polylysine glass slide and allowed to sediment for
15 min in room temperature, while treated cells were grown
directly on coverslips.
Galectin-1-Binding Glycoforms of Serum Proteins
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THP-1 cells were grown in 24-well plates containing coverslips
and were treated as described above. Cells were incubated for
30 min in serum-free medium followed by incubation with 0.2 mM
rhodamine conjugated haptoglobin-haemoglobin complex in
serum free medium at 37uC. Control experiments were performed
using 0.2 mM of rhodamine conjugated haptoglobin or haemo-
globin. Endocytosis was stopped at different time points by
removing the medium followed by addition of ice cold PBS and
fixation in 2% formaldehyde. Cells were then permeabilized with
500 ml 1% Triton-X in PBS for 10 min and washed with PBS.
Unspecific binding was prevented using blocking buffer (0.1%
Tween, 1% FBS in PBS) for 10 minutes at room temperature.
Immunostaining was performed using either of mouse a-human-
LAMP-2(a-CD107a, PharMinogen), rabbit a-rat-galectin-1
(BAbCO), mouse a-human CD163 (eBioscience) or goat a-
human-haptoglobin (Sigma-Aldrich) at a ratio of 1:100 for 1 h
at room temperature in a moist chamber. Cells were washed with
PBS and then incubated with corresponding secondary antibody
a-mouse Alexa Fluor488, a-rabbit Alexa Fluor488 and a-goat
Alexa594 (Molecular Probes, Invitrogen) at a ratio of 1:320.
Control staining with only secondary antibody was performed for
each experiment. Coverslips were mounted using Moviol with
0.01 mg/ml Hoechst 33342 (Fluka).
Image Acquisition
Phase contrast or epifluorescent images were captured using a
Nikon eclipse TE2000-U fluorescence microscope with a Plan
Apochromat 640 or a CFI Plan Apochromat 6100 oil objective:
numeric aperture 1.40, working distance 0.13 mm, and equipped
with a digital still camera DS-Qi1MC. Fluorescent images (RGB,
8 bit, 128061024) were deconvolved from a 3D stack (x,y,z
dimensions: 129.826103.85621.6 mm) with NIS-element AR
software. 5 images of each individual experiment were examined
using NIS-element AR software colocalization application and
average values of overlap coefficients according to Manders were
calculated after background correction.
Results
Affinity chromatography of serum samples on
immobilized galectin-1
Multiple human serum samples (0.1 ml) were subjected to
affinity chromatography on columns (1 ml) with immobilized
human galectin-1. To improve stability, a C3S mutant of human
galectin-1 was used, which is less sensitive to inactivation by
oxidation than wild type galectin-1 [31], and previously shown to
have the same affinity for carbohydrates and glycoproteins,
including human serum glycoproteins, as wild type galectin-1
[28]. Typical chromatograms are shown in Fig. 2A, demonstrating
that unbound proteins pass through the column without trailing
(since the curve goes down to zero during washing), and a well-
defined fraction of bound serum glycoproteins withstands the
extensive washing with buffer (32 column volumes) and can be
eluted as a sharp peak with buffer containing the competitive
ligand lactose. Modeling of the column performance [25] shows
that a binding ligand with this behavior needs an affinity of
Kd,1–5 mM or better for galectin-1. In addition, the amount of
serum ligand with this affinity for galectin-1 was confirmed by a
Figure 2. Affinity chromatography of cancer and healthy sera
on immobilized human galectin-1 C3S. A) Superimposed chro-
matograms from 5 cancer sera and 4 healthy sera. The protein
concentration of each fraction (0.2 or 1 ml) is given on Y-axis. Elution of
bound fractions with lactose (150 mM) started after washing with 32 ml
PBS (arrow heads). The chromatograms from healthy sera have been
moved for clarity by +0.05 on Y-axis and by +5 on X-axis. B) Yield of
galectin-1-binding proteins (sum of protein amount in bound fractions
multiplied by 10 to give mg per ml original serum) for sera from 25
cancer patients and 25 healthy. The average for each group is marked
by horizontal lines, and the difference was statistically significant
(p,0.0001). C) Yield of galectin-1-binding proteins from 24 cancer
patients divided based on primary tumour size. The average for each
group is marked by horizontal lines, and the difference was statistically
significant (p=0.0028).
doi:10.1371/journal.pone.0026560.g002
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[28] and galectin-3 [25].
Galectin-1 binds increased levels of glycoproteins in sera
from metastatic breast cancer patients
Twenty-five sera from women with metastatic breast cancer
(#1–25 in supportive material Table 1, median age 64 years) and
25 sera from healthy women (#26–50, median age 65 years) were
analyzed by affinity chromatography on immobilized galectin-1 as
exemplified for some in Fig. 2A. The yield of galectin-1 binding
proteins from the healthy sera was on average 1.2 mg per ml
serum (range 0.7–2.2), whereas the yield from the cancer sera was
significantly (p,0.0001) higher with an average of 2.2 mg per ml
serum (range 0.8–3.9) (Fig. 2B). The yields from the cancer
patients were compared to various aspects of the available clinical
data for each patient (Supportive material Table 1) including
pharmacological treatments (not shown). The only correlation
found was with tumour size (Fig. 2C); sera from patients with
larger primary tumours (.25 mm) gave significantly higher
average yields of galectin-1 bound glycoproteins (2.8 mg/ml
serum, p=0.0028) than smaller primary tumours (,25 mm,
1.8 mg per ml serum). Sera from patients with an inflammatory
condition but not cancer, such as IgA nephritis, did not show an
increase in galectin-1 binding glycoproteins, but rather a decrease
(not shown).
Galectin-1 binds particular forms of a selected set of
serum glycoproteins
Serum from a cancer patient was subjected to affinity
chromatography on immobilized galectin-1 as described above.
The unbound fraction was subsequently subjected to affinity
chromatography on immobilized galectin-3, which binds a much
larger fraction and wider range of human serum glycoproteins
[25]. The major glycoproteins bound by either galectin were
identified by MALDI-TOF mass spectrometry as indicated in
Fig. 3A, and the identities were confirmed by western blotting (not
shown). Galectin-1 bound mainly haptoglobin, IgM and a-2-
macroglobulin. However, only a fraction of each of these
glycoproteins were bound by galectin-1 as they were also found
in the galectin-3 bound fraction derived from the galectin-1
unbound fraction. Thus, galectin-1 binds only particular forms of
these proteins with the required affinity (Kd,1–5 mM or better). A
similar result was found when serum from a healthy individual was
applied to rat galectin-1, although less glycoproteins bound
galectin-1 in this case [25].
The major galectin-1 bound glycoproteins in all 50 serum
samples were a-2-macroglobulin, IgM and haptoglobin as
confirmed by western blots (not shown), but with considerable
variation in relative amounts between individuals, as exemplified
in Fig. 3B and shown for haptoglobin in all samples in Fig. S1. To
study these variations further, the concentrations of total and
galectin-1 bound IgM and haptoglobin were determined by
ELISA (Fig. 4).
Galectin-1 binds a specific fraction of IgM which
decreases slightly in cancer
The mean (1.5 mg/ml) and range (0.5–3.2 mg/ml) of IgM
concentrations in the healthy sera were as expected, and slightly
higher (not statistically significant) for the cancer sera (mean
1.8 mg/ml, range 0.7–4 mg/ml). The average concentration of
galectin-1 bound IgM was slightly lower in cancer sera (not
significant, Fig. 4A), due to a significant decrease (p,0.0005) in
the percentage of IgM bound to galectin-1 (mean 37% for healthy
sera and 28% for cancer sera) (Fig. 4B). In addition, and not
included in this calculation, two cancer sera and one healthy
serum did not contain any galectin-1 bound IgM (e.g. lane 4 and
29 in Fig. 3B, and dots on X-axis in Fig. 4A).
Galectin-1 binds a specific fraction of haptoglobin which
increases in cancer
The level of galectin-1 bound haptoglobin in the cancer sera
was on average about twice as high (range 0.6–4 fold) compared to
the average for control sera, (Fig. 4C) and confirmed by SDS-
PAGE (Fig. S1). This was due to the binding of a larger fraction of
haptoglobin (average 50%, range 20–80%) to galectin-1 (Fig. 4D,
X-axis) for most cancer sera that had insignificant change of the
total haptoglobin level (Fig. 4B, Y-axis), whereas for a few cancer
sera, there was an increase in total haptoglobin level, but about the
same fraction bound to galectin-1 as in control sera (average 30%,
range 25–50%). Galectin-1 affinity chromatography of purified
pooled human haptoglobin from healthy sera also resulted in a
bound fraction of about 30% that could be eluted as a sharp peak
using lactose (Fig. 4E), which was clearly distinct from the
unbound fraction (about 70%) that flowed through the column
without trailing, and gave less than 1% bound to the column when
rechromatographed.
The known peptide chain polymorphism of haptoglobin [32]
did not contribute to differences in galectin-1 binding, since SDS-
PAGE of unseparated pooled haptoglobin, the galectin-1 unbound
fraction, and the galectin-1 bound fraction, all showed the same
proportion of the a
1 chains, a
2 chains, and b chains (Fig. S2).
Moreover, all the three most common haptoglobin protein
phenotypes (with one or both of the two a-chain variants) were
represented among the 50 samples, in proportions similar to those
known for the Swedish population [32] (not shown); hence, there is
no evidence for preferential binding of any of these protein forms
by galectin-1.
Instead, with galectin-1 being a carbohydrate binding protein,
the data suggest that a subset of the different glycoforms of
haptoglobin [2,3] bind galectin-1 with high affinity, which can be
clearly distinguished from other glycoforms with no or substan-
tially lower affinity for galectin-1. Therefore, as next step we
characterized these glycoforms and incorporated the N-glycans in
known models of haptoglobin, to help inform on where galectin-1
might bind in relation to binding sites for other molecules on
haptoglobin (Fig. 1)
Characterization of galectin-1 bound and unbound
haptoglobin glycoforms
N-glycans were released from fractionated haptoglobin (galec-
tin-1–unbound and –bound as in Fig. 4E) by PNGase F treatment
and analyzed by graphitized carbon nanoLC-ion trap-MS/MS
(Figure 5); glycan compositions and structural features were
confirmed by tandem mass spectrometry (not shown). The
unbound fraction had an N-glycan-profile resembling total serum
glycoproteins, with a biantennary-disialoglycan as major species
(m/z 1112.5), the monosialylated version (m/z 966.8) as second
most predominant, and smaller amounts of triantennary and other
N-glycans. The bound fraction had two major differences, an
increased proportion of triantennary glycans (m/z 1149.5 and
1295.0), and an increased amount of a non-sialylated biantennary
glycan (m/z 821.3). The combined profile (giving 30% weight to
the bound fraction and 70% weight to the unbound fraction) is in
good agreement with previous analysis of haptoglobin N-glycans,
also including the presence of smaller amounts of fucosylated
variants indicated by red triangles in Fig. 5 [2,3].
Galectin-1-Binding Glycoforms of Serum Proteins
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26560Since haptoglobin has four known N-glycosylation sites (1–4 in
Fig. 1A), we profiled the N-glycans at separate sites by analyzing
tryptic peptides from galectin-1 bound and unbound haptoglo-
bin, using reverse phase nanoLC-ion trap-MS (Fig. S3);
glycopeptide assignments were confirmed by tandem mass
spectrometry as exemplified in Figure S4. Two singly glycosy-
lated peptides (site 1 and 4, Fig. S3A) and one doubly
glycosylated peptide (site 2 and 3, Fig. S3B) were found, together
covering the four known N-glycosylation sites of the haptoglobin
b-subunit [2,3,33]; no evidence for other glycosylation sites was
found. For the galectin-1 unbound haptoglobin, the glycosylation
profile at each site resembled that of intact unbound haptoglobin
(Fig. 5) with the predominant glycans being mono and
disialylated biantennary species. For the bound fraction the N-
glycan profile of site 1 and 4 were similar as found for the
unbound fraction, but with slightly increased presence, as minor
species, of the non-sialylated biantennary N-glycan (left panels in
Fig. S3A) and triantennary glycans (right panels). The N-glycan
profile of sites 2–3 (Fig. S3B) clearly differed, with presence of
less sialylated glycans and much increased amount of triantenn-
Figure 3. Identification of galectin-1 binding proteins in cancer and healthy sera. A) SDS-PAGE (4–20% stained with Coomassie) of bound
fractions from one healthy individual separated with affinity chromatography on galectin-1 C3S (two lanes), the unbound fraction (lane UB), and
bound fraction from the following affinity chromatography on galectin-3 (one lane). Indicated to the left are the mobilities of known size markers and
to the right mobilities of the known serum proteins a-2 macroglobulin (a2 m), transferrin (trans), IgM heavy chain (IgMh), albumin (alb), IgG heavy
chain (IgGh) and IgG light chain (IgGl), haptoglobin b chain (Hpb) and haptoglobin a chain (Hpa). In between the lanes with galectin-1 binding
fractions are indicated the proteins identified by MALDI-TOF-MS of tryptic digest of cut out bands. B) An example of SDS-PAGE of galectin-1 binding
glycoproteins from 5 healthy and 5 cancer sera (one out of five gels). The highest binding fractions (from individuals numbered as in supportive
material Table 1) were analyzed by SDS-PAGE (4–20% stained with Coomassie). Indicated to the left are the mobilities of known size markers and to
the right known serum proteins abbreviated as for A. The second lane (unlabeled) shows unseparated serum from patient 1, with albumin as the
major band.
doi:10.1371/journal.pone.0026560.g003
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with Fig. 5 and the combined profiles (giving 30% weight to the
bound fraction and 70% weight to the unbound fraction) again
agree with previous publications of haptoglobin N-glycans,
including the assignment of triantennary N-glycans mainly to
site 3 [2]. These data suggest that interaction of haptoglobin with
galectin-1 is not conferred by sites 1 and 4, but instead site 2 or 3
that are found in a region of the b-subunit away from the
Figure 4. Quantitation of total and galectin-1 bound IgM and haptoglobin in cancer and healthy sera. A) The concentrations of IgM in
the galectin-1 bound fractions from cancer (n=25) and healthy sera (n=25) as determined by direct enzyme-linked immunosorbent assay (ELISA).
The average for each group is marked by horizontal lines, but the slight difference was statistically not significant (p=0.41). B) Initial serum levels of
IgM (Y-axis) compared to % of galectin-1 bound IgM (X-axis). The averages and ranges of each parameter are shown by crossed lines, unbroken for
cancer sera and dashed for healthy sera. The difference between the % galectin-1 bound IgM was significant (p,0.0001) but the difference between
total IgM was not (p=0.24). The three samples with no galectin-1 bound IgM (seen as dots on Y axis) were excluded from the calculation of averages,
ranges and significances shown; including them made only a minor change in averages and no change in significance of differences. C) The
concentrations of haptoglobin in the galectin-1 bound fractions from cancer (n=25) and healthy sera (n=25) as determined by direct ELISA. The
average for each group is marked by horizontal lines, and the difference was statistically significant (p,0.0001). Error bars represent SEM from three
independent duplicate measurements for each data point. D) Initial serum levels of haptoglobin (Y-axis) compared to % of galectin-1 bound
haptoglobin (X-axis). The averages and ranges of each parameter are shown by crossed lines, unbroken for cancer sera and dashed for healthy sera.
The difference between the % galectin-1 bound haptoglobin was significant (p,0.0001) and the difference between total haptoglobin was also
significant (p=0.0058). E) Chromatograms of 2 mg purified pooled haptoglobin separated by affinity chromatography on columns (1 ml) with
immobilized galectin-1 C3S. The protein concentration of each fraction (0.2 or 1 ml) is given on Y-axis. Elution with lactose (150 mM) started after
washing with 32 ml PBS (arrow heads). Non-binding haptoglobin was chromatographed a second time but only traces (,1%) of additional
haptoglobin was now found in the bound fraction. The chromatogram from the second run has been moved for clarity by +0.05 on Y-axis and by +5
on X-axis.
doi:10.1371/journal.pone.0026560.g004
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CD163 (Fig. 1A).
Evidence for a specific binding site for galectin-1 on
haptoglobin
Previously we have shown that galectin-1 interacts with serum
glycoproteins mainly in a monovalent fashion and that interaction
with only one of its CRDs is sufficient for binding as defined here
(that is binding to the affinity column requiring Kd in low mM
range) [28]. Thus, interaction with only one N-glycan on a whole
haptoglobin molecule (Fig. 1C) would be sufficient, which will be
1/8 of the total for a ab dimer, 1/12 for a trimer and a smaller
fraction for higher oligomers; with this calculation for pooled
haptoglobin, as analyzed here, the galectin-1 binding N-glycan
needs to be at most about 10% of the total N-glycans and at most
about 30% of those at a specific N-glycosylation site.
LacNAc is by far the major b-galactoside on serum glycoprotein
and is expected to be bound in the core binding site (C–D) of the
galectin (the LacNAc residues shown in black in Fig. 1C). By itself,
however, it binds galectin-1 only with a Kd of 100–200 mM
[28,34], which is too weak to confer the binding observed here.
The potency of total haptoglobin (counted as the dimer) as an
inhibitor in the fluorescence anisotropy assay corresponded to an
average Kd of ,2.5 mM (Table S2), and thus for the 30% bound
fraction estimated to be less than 1 mM. Therefore some additional
interactions must be required. Making variants of natural serum
haptoglobin, with altered glycosylation and/or peptide sequence,
to identify these interactions is very difficult or impossible at the
present time. Instead we made mutants of galectin-1 to identify
what aspects of its binding properties are required for its binding to
serum glycoproteins and haptoglobin (Table S2 and Fig. S5).
One set of mutants were made in site B of the galectin (see Refs
[20,28] for detailed description of the 5 subsites (A–E) of the
galectin carbohydrate binding groove), to alter interactions of the
galectin with moieties linked to the 3-position of the Gal in
LacNAc, in analogy with mutants previously made of galectin-3
[28]. Galectin-1 binds terminal LacNAc residues and those
carrying sialic acid [35] or sulphate [36] at the 3-position of
Gal, but in contrast to galectin-3 it does not tolerate other
extensions, e.g. by GlcNAcb as found in polylactosamines
(represented by GlcNAcm1-3Lac in Table S2). Two mutants,
N34D and S30G had selectively reduced tolerance for 3-sialylated
galactosides, but bound terminal LacNAc with about equal affinity
as galectin-1 C3S (Table S2). These mutants also bound less serum
glycoprotein and haptoglobin, in rough proportion to their loss of
tolerance for sialylation, suggesting that the main high affinity
binding site for galectin-1 includes a 3-sialylated galactoside. To
determine if 3-linked sialic acid was required for binding or only
needed to be tolerated, neuraminidase treated serum was
analyzed. This treatment restored binding of serum glycoproteins
to the N34D mutant to a level similar to wild type galectin-1.
Figure 5. Mass spectrometric analysis of N-glycans from galectin-1 bound and unbound haptoglobin. Enzymatically released N-glycans
from galectin-1 bound (top panel) and unbound (bottom panel) haptoglobin (pooled from human plasma, separated as described in S5) were
analyzed by nano-LC-ESI-ion trap-MS. N-glycans were detected in double-protonated form giving m/z values about equal to half the molecular
weight. Schematics of the glycans corresponding to the major peaks are shown, with symbols as described for Fig. 1C. Some minor peaks show
glycans with an additional fucose residue (red triangle) as indicated by a double-headed arrow. Other minor peaks correspond to tetraantennary
glycans with 0, 1 or 2 NeuAc residues (m/z1186.1, 1332.0 and 1477.6, respectively). #, natrium proton mixed adducts; *, single charged contaminants.
doi:10.1371/journal.pone.0026560.g005
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binding.
2–3 sialylated galactosides have been found only in triantennary
N-glycans in human serum (e.g. like structure 3 of Fig. 1B), and in
haptoglobin predominantly at site 3 [2,3,37]. The intensity of the
peaks for triantennary glycans in the mass spectra of the galectin-1
bound haptoglobin N-glycans (Fig. 5 and Fig. S3), even if only
semiquantitative, suggest that their percentages of the total are
sufficient to account for the galectin binding (.10% of the total
and .30% at site 3). 3-O sulfated galactosides have been shown to
bind galectin-1 with enhanced affinity [36,38] but they would have
been detected by the mass spectrometry employed here, and
hence, are not likely candidates as galectin-1 binding sites on
haptoglobin.
Another site B mutant of galectin-1, V32A, opens the ability to
bind GlcNAcb1-3 substituted galactosides (Table S2), as found in
internal Gal-residues of polylactosamines (repeating LacNAc
residues). This does not appear to be important for binding to
serum glycoproteins, as this mutant bound the same amount and
profile of glycoproteins as galectin-1 C3S. Previous studies have
suggested high affinity (Kd in mM range or better) binding of
galectin-1 to polylactosamines, but later studies have shown that
galectin-1 only binds terminal LacNAc residues, and the apparent
preference for polylactosamines in some assays is to put these far
enough out [39,40]; in fact polylactosamines do not bind galectin-
1 better than the ordinary types of N-glycans shown here on
haptoglobin [27,41]. Polylactosamines have not been reported
among human serum N-glycans despite studies by many groups,
making them unlikely binding sites for galectin-1 in the present
study. Nevertheless, to further assess their role for the binding of
galectin-1 to serum glycoproteins, we passed a serum sample
through a column with immobilized tomato-lectin, known to bind
polylactosamines selectively [40], and then analyzed the flow
through on immobilized galectin-1 as described above. There was
no significant reduction in recovery of galectin-1 bound glycopro-
teins, suggesting that most of the binding to galectin-1 to serum
glycoproteins is not mediated by polylactosamines. In addition no
serum proteins were found when a sample from the top of the
tomato-lectin column was boiled in sample buffer and analyzed by
SDS-PAGE (not shown).
One mutant in site E, R74S, near the reducing end of LacNAc
in site C–D, was also tested. This mutant was harder to produce
and, therefore, not tested in affinity chromatography. However, in
inhibition assays it was clear that it had dramatically reduced (.8
fold) affinity for haptoglobin even if its affinity for LacNAc was
identical to wild type galectin-1 (Table S2). This strongly suggests
that for high affinity binding, galectin-1 also has to interact with
parts of the N-glycan near the reducing end of LacNAc or with
nearby protein parts.
The non-sialylated biantennary N-glycan (#1 in Fig. 1B) was
also enriched in the galectin-1 bound haptoglobin fraction and
present in sufficient amount to be a galectin-1 binding site.
However, by itself it is a weak ligand for galectin-1 (Kd about
100 mM, [28]), and less than 2% of neuraminidase treated
transferrin that carries almost only this glycan bound galectin-1
(Fig. S6). Thus, together with the data presented above, this
strongly suggests that a major recognition site for galectin-1 on
haptoglobin is a triantennary N-glycan, such as #3 of Fig. 1B, but
binding to other glycans (e.g. #1 and 2) cannot be ruled out if they
are presented in a particularly favorable way in conjunction with
the protein.
High affinity binding of galectin-1 could also, theoretically, be
caused by interaction with multiple available binding sites on the
same glycoprotein molecule, where high affinity is either caused by
simultaneous binding of a galectin-1 dimer at two sites, or by a
recapture effect [34]. However, our previous studies argued
against these mechanisms [28], e.g. showed that a dimerization
deficient mutant of galectin-1 bound serum glycoproteins with
equal affinity as wild type, and instead as mentioned above,
showed that galectin-1 interaction with glycoproteins is largely
monovalent. Moreover, divalent binding of a galectin-1 dimer to
two N-glycans within the same haptoglobin subunit is not possible
because the galectin-1 carbohydrate binding sites are too far apart
and have opposite directions (black surfaces in yellow model in
Fig. 1C). Divalent binding between two subunits of a haptoglobin
multimer is also unlikely as galectin-1 would not reach far enough.
From the above we conclude that one specific site on a
haptoglobin molecule interacts with one CRD of the galectin-1
dimer, leaving the other open for interaction with cellular
glycoproteins involved in the function of haptoglobin. This is not
likely to be functionally significant in serum or plasma itself since
there the concentration of galectin-1 dimer is very low (,1n M
[42], ,3 nM (not detected) as confirmed here for 5 of the healthy
and cancer samples. Instead we tested the possibility that
interaction with galectin-1 in cellular compartments, where its
concentration may be much higher, is important for the function
of haptoglobin.
Different intracellular localization of galectin-1 binding
and non-binding haptoglobin after endocytosis in
macrophages
The major function of haptoglobin is to capture free
haemoglobin (Hb) released in the circulation during haemolysis,
resulting in clearance of potentially oxidative and toxic iron groups
that haemoglobin contains [43]. The Hp-Hb complex can then be
internalized through binding of haptoglobin to CD163, a
scavenger receptor expressed on the surface of cells from the
macrophage lineage [44], in particular in alternatively activated
anti-inflammatory macrophages [45,46].
In order to study the relationship between these processes and
the galectin-1 binding of haptoglobin, we made complexes of
haemoglobin with galectin-1 unbound and bound haptoglobin
(Fig. S7A), and studied their uptake into THP-1 cells, differenti-
ated with PMA and alternatively activated by IL-4 as a
macrophage model [47]. The PMA treated THP-1 cells became
adherent as expected, and after the additional IL-4 activation they
became larger and more granular (Fig. S7B) and showed specific
staining for CD163, albeit sparse (not shown).
The cells were functionally characterized by incubation with
0.2 mM rhodamine labeled haptoglobin, haemoglobin, or Hp-Hb
complex (galectin-1 non-bound) followed by epifluorescence
microscopy to follow uptake. Haptoglobin was not internalized
after 30 minutes in any of the THP-1 cells tested, and also not in a
number of other galectin-1 expressing cell lines (CHO, HFL-1,
SkBr3) (not shown). Treatment of cells with 0.2 mM haemoglobin
for 30 minutes, as expected, resulted in cell death (cell shrinkage,
nuclear fragmentation and detachment). In contrast, the Hp-Hb
complex was internalized in the PMA+IL-4 stimulated THP-1
cells after 30 min, but not in the cells stimulated with PMA only
(Fig. S7C). Galectin-1 was found in the cytosol and nuclei as
known for other cell types but also in larger granules, and its
staining pattern was more distinctly vesicular and ‘‘patchy’’ in the
IL-4 stimulated THP-1 cells (not shown), similar to Jurkat T-
lymphocyte cells as previously described by Fajka-Boja et al. [48].
Rhodamine labeled galectin-1 binding or non-binding Hp-Hb-
complexes (0.2 mM) were added to the PMA+IL-4 stimulated
THP-1 cells and the intracellular localization was analyzed after 5,
15 and 30 min by deconvolution fluorescence microscopy. The
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intracellular distribution compared to the non-binding Hp-Hb
(Fig. 6A) already after 5 min, and even more pronounced after 15
and 30 min. The galectin-1 binding Hp-Hb-complex was found in
large granule like vesicles, which were also stained by an anti-
galectin-1 antibody (green in Fig. 6B). In contrast, the galectin-1
non-binding complexes did not colocalize with galectin-1, but
instead with LAMP-2 (green in Fig. 6C), a marker for late
endosomes and lysosomes [49]. The colocalization was quantitat-
ed using the overlap coefficient of Manders, which gives the true
degree of colocalization (e.g. Manders coefficient 0.5 implies that
50% of the two selected channels co-localize) [50]. As expected,
the added galectin-1 binding Hp-Hb-complex showed a significant
overlap (Manders coefficient; 15 min: 0.81 and 30 min: 0.79) with
endogenous galectin-1 (Fig. 6B), whereas non-binding Hp-Hb-
complex showed hardly any overlap with galectin-1 (Manders
coefficient; 15 min: 0.47 and 30 min: 0.42). In contrast, staining
with LAMP-2 antibody showed a considerable overlap with non-
binding Hp-Hb-complex (Manders coefficient 0.91) but not with
galectin-1 binding Hp-Hb-complex (Manders coefficient 0.29)
(Fig. 6C). Thus, two subpopulations of human haptoglobin
glycoforms, separated based on their binding to galectin-1, form
complexes with Hb that are subsequently sorted to different
endocytic compartments in macrophages.
Discussion
The present results demonstrate that a significant fraction of
human serum a-2-macroglobulin, IgM and haptoglobin, bind to
galectin-1 and that the total amount of galectin-1-binding
glycoproteins can be 2–3 times larger in sera of some cancer
patients. If albumin and IgG, both of which do not bind galectin-1,
are excluded, galectin-1 binds approximately 10–15% of the
remaining glycoproteins in healthy sera and up to 40% in cancer
Figure 6. Endocytosis and intracellular trafficking of galectin-1 unbound and bound haptoglobin-haemoglobin complex in
macrophages. A) THP-1 cells treated to differentiate with PMA for 5 days, and alternatively activated with Il-4 for 2 days were incubated with 0.2 mM
rhodamine-labeled galectin-1-non-binding (left panel) or -binding (right panel) haptoglobin (pooled from human plasma, separated as described in
Fig. S5) in complex with haemoglobin (red) for 5, 15 or 30 minutes at 37uC in order to allow endocytosis to occur. Cells were fixed in formaldehyde,
nuclei stained blue with Hoechst, and cells observed by deconvolution fluorescence microscopy (1006). Scale bar represents 10 mm. B) Images from
Panel A in combination with immunostaining for galectin-1 (green). Extensive colocalization of galectin-1-binding haptoglobin-haemoglobin and
galectin-1 is revealed by the overlap of signals in merged images that results in yellow staining. The bottom panels show a larger magnification of the
boxed areas from the top panels. Scale bar represents 10 mm. C) Cells were treated as for panels A and B except that they were immunostained for
LAMP-2 (instead of galectin-1), a marker for late endosomes and lysosomes. Extensive colocalization of galectin-1-non-binding haptoglobin-
haemoglobin and LAMP-2 is revealed as yellow staining.
doi:10.1371/journal.pone.0026560.g006
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mechanism, 2) what is the functional consequence, and 3) what is
the diagnostic value?
The mechanism was studied in detail for haptoglobin. The
composition of N-glycans of galectin-1 bound and unbound
haptoglobin was analyzed (Fig. 5 and S3) and incorporated into
models of haptoglobin (Fig. 1). Together with previous knowledge
that the interaction with galectin-1 is mainly monovalent [28], the
data suggest that interaction of one galectin-1 CRD with one N-
glycan on haptoglobin is sufficient for binding. This interaction
must involve some special feature of the N-glycan and probably
also neighboring parts of the protein. The loss of binding of the
N34D mutant suggests that the binding site includes a 2–3
sialylated galactose residue, such as has been found on the third
antenna of triantennary N-glycans in serum and haptoglobin
(structure in Fig. 1), but additional interactions are most likely also
required to reach the affinity observed. Since each haptoglobin
molecule contains 8 or more N-glycans (Fig. 1C), the galectin-1
binding glycan accounts for only 10% or less of these, and
therefore other N-glycans, not binding galectin-1, are carried
along in the galectin-1 bound fraction. These other glycans may
also be part of a cancer related glycan profile, if, for example, the
haptoglobin comes from cancer cells, as proposed [51], or liver
cells indirectly affected by the presence of cancer elsewhere in the
body. Therefore, previous studies and the present study may have
detected overlapping sets of cancer related haptoglobin glyco-
forms. For example, the fucosylated N-glycans, albeit quantita-
tively minor, that were found in increased amounts on haptoglobin
from different cancer patient sera [2,3], were also found enriched
in the galectin-1 bound fraction (indicated by red triangles in
Fig. 5), even if such antennary fucose (linked to 3 position of
GlcNAc) would block galectin-1 binding [20].
The proposed one site mechanism for galectin-1 binding to
haptoglobin may also explain binding to IgM and a2-macroglob-
ulin, although further studies like the ones applied here to
haptoglobin are required to confirm this. Each IgM pentamer has
at least 51 N-glycosylation sites (5 conserved for each of the 10
heavy chains +1 for the J-chain) [52]. Thus an N-glycan conferring
high affinity galectin-1 binding to IgM needs to be present only as
,1% to explain the binding of about 30% IgM as found here.
Therefore, triantennary complex N-glycans may explain binding
of galectin-1 also to IgM even if they occur only as very minor
species [52]. By an analogues argument, the binding of a major
part of a2-macroglobulin to galectin-1 can also be explained; this
tetrameric glycoprotein carries 32 N-glycans (8 per subunit) and
triantennary complex N-glycans are well above the 3% (one per
molecule) required for galectin-1 binding [53]. While there is an
increasing number of reports suggesting changes in O-linked
glycosylation as the major cancer-associated post-translational
modification [54], this will most likely not be the source of
increased galectin-1 binding of serum glycoproteins. First, none of
the three galectin-1 bound glycoproteins carry any known O-
glycan, while their N-glycosylation is well characterized. Second,
IgA, the major O-glycosylated protein in serum is not bound by
galectin-1 [25], and third the major cancer associated O-glycans,
the T antigen (Galb1-3GalNAca) and Tn-antigen (GalNAca) are
poor ligands to human galectin-1[35,55].
The binding of one galectin-1 CRD to haptoglobin leaves the
other available to cross-link it to other glycoproteins in the tissue
cell, which we believe is the function of this interaction. The
interaction is not likely to be significant in serum itself, because
there the measured concentration of galectin-1 dimer is ,1n M
[42] compared to .1 mM, i.e. more than 1000 fold more, for
either of the main bound glycoproteins. After exit from the blood
stream, however, serum glycoproteins will encounter high
concentrations of galectins (mM) in tissue cells, with possible
mutual functional effects as discussed by Cederfur et al. [25]. Here
we show that the interaction of haptoglobin with galectin-1
becomes decisive after haptoglobin has carried out its highly
specialized function – to form a tight complex with haemoglobin
that binds to the scavenger receptor CD163 in alternatively
activated macrophages and becomes endocytosed [43]. At this
point galectin-1 binding appears to divert the complex from
targeting into late endosomes and lysosomes, perhaps for
degradation, and instead targets it to another set of larger vesicles
for an as yet unknown function (Fig. 6). On average 30% of
haptoglobin from healthy sera take this route, whereas for cancer
sera it may be up to 80%. This suggests that this is a major
regulatory step in the scavenging of haemoglobin by haptoglobin,
and that this regulation can be dramatically altered in cancer.
Macrophages are abundant in breast carcinoma and reports
suggest that these TAMs (tumour associated macrophages) exhibit
an alternatively activated (MW2-like) functional profile and are
CD163 positive [56,57]. Thus one may speculate what would be
the effect of the galectin-1 regulated balance between the different
fates of Hp-Hb within these macrophages. For example, if the
binding of haptoglobin to galectin-1 increases, more of the
complex could end up in galectin-1 containing granules instead of
being directed to the degradation pathway, which could influence
haptoglobin and haemoglobin activities such as angiogenesis [58].
The other galectin-1 binding proteins were not analyzed in
detail in this study, but a few points may still be made. Total IgM
was slightly higher in cancer sera but the percentage bound to
galectin-1 lower. This suggests that the IgM induced under the
cancer condition may have decreased binding to galectin-1 with
possible connection to its origin and function in the immune
system. Another interesting finding was the three cases (two cancer
sera and one healthy serum) with no galectin-1 binding IgM.
There was no apparent correlation with the total amount of IgM
or galectin-1 bound or unbound fraction of the other glycopro-
teins. These ‘‘outliers’’ may instead be the result of genetic
polymorphisms, perhaps affecting N-glycosylation of IgM or a
particular glycosyltransferase in B-cells. With the recent emer-
gence of large scale profiling of N-glycans in human serum, genetic
variants have begun to be discovered in the normal population
[5,59].
To address the final question on the diagnostic usefulness of
galectin-1 binding serum glycoproteins, further studies are needed.
These needs to include a larger number of cases, and cases of
different stages of cancer development, especially early. This
should also include comparison with sera from patients with
benign breast disease. However, the purpose here was only to
analyze if there was any difference between sera from patients with
severe cancer and healthy controls (selected to be as similar to the
patients as possible) at all. Already now it is clear that the
quantitation of galectin-1 binding glycoforms is able to discrim-
inate sera from patients with established metastatic cancer, as
studied here, from sera from healthy controls. For the concentra-
tion of galectin-1 bound haptoglobin as the measured parameter,
ROC plots (Fig. S8) gave an area under the curve (AUC) of about
0.90. This was also the case for percentage of galectin-1 bound
IgM, and a combination (ratio) of the two parameters gave an
AUC of 0.95. These values being .0.90 are considered excellent
in the field, and are equally good or better than other proposed
biomarkers for cancer in serum [8,9,26,60].
Thus, further study of galectin-binding glycoforms of serum
proteins is likely to be highly fruitful, but has been studied to a very
limited extent so far. One study found strongly increased binding
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from cancer patients, but only after desialylation [51]. Other
earlier studies have found variable correlation between cancer and
serum levels (low mg/ml) of the Mac-2-binding protein, named
based on its affinity for galectin-3 [61]. Currently there is a great
need for improved diagnostic biomarkers for breast and prostate
cancer. Even one of the best markers established, PSA in prostate
cancer, has significant overlap between non-cancer and cancer
cases and due to its low sensitivity and specificity (area under
ROC-curve typically ,0.7, [62]) it is not widely used for
population screening [63]. Most tumour markers currently used
in clinics are serum glycoproteins (PSA, CA-125 and CEA);
although usually the protein itself is detected, some tumour
associated antigens consist of attached carbohydrates. In the
evolving field of cancer biomarkers discoveries, detection of
glycosylation changes is considered to be the frontline of future
diagnostics, since they are capable of increasing sensitivity and
specificity of existing protein-based assays [8,64]. The studies here
provide a novel approach because firstly, the cancer related
glycoforms are detected using an endogenous lectin (galectin-1)
that they are likely to interact with in vivo, and secondly because we
show that this interaction results in a different function relevant for
cancer. Thirdly, these functionally different glycoforms may make
up a large proportion of major serum glycoproteins such as
haptoglobin (up to 80% in some cases), making it likely that they
reflect a changed physiological state of the patient.
Supporting Information
Figure S1 Quantitation of galectin-1 C3S bound hapto-
globin in cancer and healthy sera. (A) Intensities of
haptoglobin heavy chain bands on SDS-PAGE gels (shown
cropped) were estimated using histogram data from ImageJ
(National Institutes of Health) using one of the known size markers
as an internal control for each gel. Intensities are given in arbitrary
units (AU) under each band, and sample number is given above it,
with #1–25 from cancer patients and #26–50 from healthy
controls (Table 1). (B) Haptoglobin band intensities (arbitrary
units) for cancer patients and healthy controls. The average for
each group is marked by horizontal lines.
(TIF)
Figure S2 SDS-PAGE of haptoglobin from pooled
healthy sera separated on immobilized galectin-1 C3S.
Unseparated (US), galectin-1 C3S unbound (UB1 circulated
fraction, UB2 wash fraction) or bound (B) haptoglobin were
analyzed by SDS-PAGE (4–20% stained with Coomassie).
Indicated to the left are the mobilities of known size markers
and to the right the different haptoglobin chains.
(TIF)
Figure S3 A. Glycosylation analysis of site 1 (N59) or 4
(N116) of galectin-1 C3S bound and unbound haptoglo-
bin. Tryptic glycopeptides were identified by nano-LC-ESI-ion
trap-MS, and MS peaks are shown for those carrying the six major
N-glycans (schematics above with symbols as in Fig. 5). For site 1
(N59) they were detected as double peaks due to partial oxidization
(ox) of methionine giving a 16 Da mass shift. B. Glycosylation
analysis of site 2 (N59) and 3 (N116) of galectin-1 C3S
bound and unbound haptoglobin. Tryptic glycopeptides
containing the two sites were identified by nano-LC-ESI-ion trap-
MS, and MS peaks are shown for those carrying the major
detected combinations of N-glycans (schematics above mass
spectra).
(PDF)
Figure S4 Tandem mass spectrometry of glycopeptide
M54-K77 carrying a biantennary, non-sialylated N-
glycan. The quadruple protonated glycopeptide was subjected
to ion trap-MS/MS analysis.
(TIF)
Figure S5 Affinity chromatography of serum and hap-
toglobin on galectin-1 C3S mutants. (A) Serum from a
healthy individual was analyzed using galectin-1 C3S and three
further mutants in site B. Only the lactose eluted fractions are
shown. Conditions are identical as in Fig. 2. (B). SDS-PAGE of
peak bound (BF) and unbound (N-BF) fractions from the
experiment of (A). The unfractionated serum (St.fr.) and size
markers are shown to the left. All bound fractions showed the same
pattern of proteins with a-2-macroglobulin, IgM and haptoglobin
as major species, except that mutant N34D bound less of all, most
clearly visible for haptoglobin. (C) Affinity chromatography on
galectin-1 C3S and C3S N34D of serum treated or not treated
with Vibrio cholerae neuraminidase. N34D binds much less
untreated serum glycoproteins, but neuraminidase restores
binding to equal levels as for galectin-1 C3S. (D) Affinity
chromatography of haptoglobin (from pooled human plasma
(Sigma-Aldrich)) on galectin-1 C3S and C3S N34D.
(TIF)
Figure S6 Human transferrin analyzed by affinity
chromatography on galectin-1 C3S or galectin-3. 2m g
of human transferrin were analyzed using galectin-1 and galectin-3
coupled 1 ml affinity columns. As predicted galectin-1 does not
bind human transferrin, while approximately 6% bind galectin-3
(top panel). The galectin-3 non-binding transferrin was treated or
not treated with Vibrio cholerae neuraminidase (NA) (0.1 mmol 1 h at
37uC), and again analyzed on galectin-3 or galectin-1 coupled
affinity columns. Removal of sialylations generated an additional
4% of galectin-3 binding transferrin (middle panel), but only traces
(about 1.5%) of galectin-1 binding transferrin (bottom panel).
(TIF)
Figure S7 Analysis of haptoglobin-haemoglobin com-
plex in macrophages. A) Native gel electrophoresis of
haptoglobin-haemoglobin complex. Haptoglobin (left) moved into
the gel, while haemoglobin (middle) did not. For the haptoglobin-
haemoglobin complex (right) the free haptoglobin band had
disappeared from the gel, indicating that the complex had formed.
B) Light microscope images (406) of THP-1 cells, untreated,
induced to differentiate with PMA (5 days), or in addition IL-4 (2
days) for alternatively activation. Untreated cells were transferred
to a polylysine glass slide and allowed to sediment for 15 min at
room temperature before microscopy, while treated cells were
grown directly on coverslips. Scale bar represents 50 mm. C)
Uptake of Hp-Hb complex in differentiated and activated THP-1
cells. THP-1 grown in the presence of PMA (5 days) or PMA (5
days) +IL-4 (2 days) were incubated with 0.2 mm NHS-
sulphorhodamine conjugated galectin-1 non-binding haptoglobin
in complex with haemoglobin for 30 minutes. Cells were fixed in
formaldehyde and analyzed by fluorescence microscopy (406).
Nuclei were stained blue with Hoechst. Scale bar represents
50 mm. All microscopy images were taken with a Nikon Eclipse
TE2000-E fluorescence microscope.
(TIF)
Figure S8 Receiver operating characteristic (ROC)
curve analysis for different measured parameters to
distinguish sera from breast cancer patients from
controls. A) Concentration of galectin-1 bound haptoglobin, B)
percentage of galectin-1 bound IgM, and C) ratio of the
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PLoS ONE | www.plosone.org 13 October 2011 | Volume 6 | Issue 10 | e26560percentages of galectin-1 bound haptoglobin and IgM. The area
under the curve (AUC) indicates the discriminatory power of the
measured parameter. A value .0.90 is considered excellent.
(TIF)
Table S1 Subjects and respective amount of galectin-1
ligands in sera.
(TIF)
Table S2 Relative affinity of galectin-1 proteins for
small saccharides and haptoglobin.
(DOCX)
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